[1] Lillibridge CB, Docter JM, Eidelman S. Oral administration of n-acetyl cysteine in the prophylaxis of “meconium ileus equivalent”. J Pediatr. 1967 Dec;71(6):887-9.
[2] Gracey M, Burke V, Anderson CM. Treatment of abdominal pain in cystic fibrosis by oral administration of n-acetyl cysteine. Arch Dis Child. 1969 Jun;44(235):404-5.
[3] Olsson B, Johansson M, Gabrielsson J, Bolme P. Pharmaco*kinetics and bioavailability of reduced and oxidized N-Acetyl-L-Cystein e. Eur J Clin Pharmacol. 1988;34(1):77-82.
[4] Borgström L, Kågedal B, Paulsen O. Pharmaco*kinetics of N-Acetyl-L-Cystein e in man. Eur J Clin Pharmacol. 1986;31(2):217-22.
[5] Holdiness M.R. Clinical pharmaco*kinetics of N-Acetyl-L-Cystein e. Clin. Pharmaco*kinet. 1991;20:123–134.
[6] N.N. Hekmat, D. Cicek: Acetylcystein; Fortbildungstelegramm Pharmazie; Heinrich-Heine-Universität, Düsseldorf, 2013;7(2):60-74
[7] Kopke RD, Coleman JKM, Liu J, Jackson RL, Van De Water TR. Mechanisms of noise-induced hearing loss and otoprotective strategies.
In: Van De Water TR, Staecker H, editors. Otolaryngology: basic science and clinical review. New York: Thieme;2006. p.395-408.
[8] Arranz L, Fernández C, Rodríguez A, Ribera JM, De la Fuente M. The glutathione precursor N-Acetyl-L-Cystein e improves immune function in postmenopausal women. Free Radic Biol Med. 2008 Nov 1;45(9):1252-62.
[9] M. G. Tom`as Casanova, N-Acetyl-L-Cystein e: An old drug with variable anti-influenza properties, Journal of Controversies
in Biomedical Research, vol. 2, no. 1, pp. 1–8, 2016.
[10] T. Origuchi, K. Migita, T. Nakashima:Regulation of cyclooxygenase-2 expression in human osteoblastic cells by N-Acetyl-L-Cystein e.In:J Lab Clin Med.Band 136, Nr. 5, Nov 2000, S. 390–394.
[11] S. Uraz, N-Acetyl-L-Cystein expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic acid-induced colitis in rats, Scandinavian Journal of Clinical and Laboratory Investigation,
vol. 73, no. 1, pp. 61–66, 2013.
[12] . Zhitkovich, N-Acetyl-L-Cystein e: Antioxidant, aldehyde scavenger, and more, Chemical Research in Toxicology, 32, 7, 1318-1319, 2019.
[13] Tardiolo G, Bramanti P, Mazzon E. Overview on the Effects of N-Acetyl-L-Cysteine in Neurodegenerative Diseases. 2018 Dec 13;23(12):3305.
[14] Bavarsad Shahripour R, Harrigan MR, Alexandrov AV. N-Acetyl-L-Cystein e (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav. 2014 Mar;4(2):108-22.
[15] Fass D, Thorpe C. Chemistry and Enzymology of Disulfide Cross-Linking in Proteins. Chem Rev. 2018 Feb 14;118(3):1169-1198.
[16] Sochman J. N-Acetyl-L-Cystein e in acute cardiology: 10 years later: What do we know and what would we like to know? J. Am. Coll. Cardiol. 2002;39:1422–1428. doi:10.1016/S0735-1097(02)01797-7.
[17] P. Ghezzi, Role of glutathione in immunity and inflammation in the lung, International Journal of General Medicine, 4, 105–113, 2011.
[18] Fowdar K, Chen H, He Z, Zhang J, Zhong X, Zhang J, Li M, Bai J. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review. Heart Lung. 2017 Mar-Apr;46(2):120-128.
[19] Shi Z, Puyo CA. N-Acetylcysteine to Combat COVID-19: An Evidence Review. Ther Clin Risk Manag. 2020;16:1047-1055.
[20] D. A. Rossignol, The use of N-Acetyl-L-Cystein e as a chelator for metal toxicity, Therapeutic Use of N-Acetyl-L-Cysteine (NAC) in Medicine, R. E. Frye and M. Berk, Eds., Springer, Singapore, Singapore, 169–179, 2019.
[21] Mokhtari V, Afsharian P, Shahhoseini M, Kalantar SM, Moini A. A Review on Various Uses of N-Acetyl Cysteine. Cell J. 2017 Apr-Jun;19(1):11-17.
[22] Schwalfenberg GK. N-Acetyl-L-Cystein e: A Review of Clinical Usefulness (an Old Drug with New Tricks). J Nutr Metab. 2021 Jun 9;2021:9949453.
[23] Deepmala, N. Kumar, M. Berk et al., Clinical trials of N-Acetyl-L-Cystein e in psychiatry and neurology: a systematic review, Neuroscience and Biobehavioral Reviews, vol. 55, 294–321, 2015.
[24] Kutlu MG, Zachry JE, Melugin PR, Cajigas SA, Chevee MF, Kelly SJ, Kutlu B, Tian L, Siciliano CA, Calipari ES. Dopamine release in the nucleus accumbens core signals perceived saliency. Curr Biol. 2021 Nov 8;31(21):4748-4761.
[25] Offen D, Ziv I, Sternin H, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson’s disease. Exp Neurol. 1996 Sep;141(1):32-9.
[26] Y. Hara, “Evaluation of the neuroprotective potential of N-Acetyl-L-Cystein e for prevention and treatment of cognitive aging and dementia,” Journal of Prevention of Alzheimer’Disease, 4, no. 3, 201–206, 2017.
[27] Joy T, Rao MS, Madhyastha S, Pai K. Effect of N-Acetyl Cysteine on Intracerebroventricular Colchicine Induced Cognitive Deficits, Beta Amyloid Pathology, and Glial Cells. Neurosci J. 2019 Apr 15;2019:7547382.
[28] Dröge W, Breitkreutz R. Glutathione and immune function. Proc Nutr Soc. 2000 Nov;59(4):595-600.
[29] Braakhuis AJ, Hopkins WG. Impact of Dietary Antioxidants on Sport Performance: A Review. Sports Med. 2015 Jul;45(7):939-55.
[30] Fernández-Lázaro D, Domínguez-Ortega C, Busto N, Santamaría-Peláez M, Roche E, Gutiérez-Abejón E, Mielgo-Ayuso J. Influence of N-Acetyl-L-Cystein e Supplementation on Physical Performance and Laboratory Biomarkers in Adult Males: A Systematic Review of Controlled Trials. Nutrients. 2023 May 25;15(11):2463.
[31] Tenório MCDS, Graciliano NG, Moura FA, Oliveira ACM, Goulart MOF. N-Acetyl-L-Cystein e (NAC): Impacts on Human Health. Antioxidants (Basel). 2021 Jun 16;10(6):967.
[32] Johnson K., McEvoy C.E., Naqvi S., Wendt C., Reilkoff R.A., Wetherbee E.E., Nelson D., Tirouvanziam R., Niewoehner D.E. High-dose oral N-Acetyl-L-Cystein e fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: A randomized, placebo-controlled trial. Int. J. COPD. 2016;11:799–807.
[33] Arstall M.A., Yang J., Stafford I., Betts W.H., Horowitz J.D. N-Acetyl-L-Cystein e in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction: Safety and biochemical effects. Circulation. 1995;92:2855–2862.
[34] Ozaydin M., Peker O., Erdogan D., Kapan S., Turker Y., Varol E., Ozguner F., Dogan A., Ibrisim E. N-Acetyl-L-Cystein e for the prevention of postoperative atrial fibrillation: A prospective, randomized, placebo-controlled pilot study. Eur. Heart J. 2008;29:625–631.
[35] Kishi T., Miyake N., Okuya M., Sakuma K., Iwata N. N-Acetyl-L-Cystein e as an adjunctive treatment for bipolar depression and major depressive disorder: A systematic review and meta-analysis of double-blind, randomized placebo-controlled trials. Psychopharmacology. 2020;237:3481–3487.
[37] https://go.drugbank.com/drugs/DB06151
[38] https://pubchem.ncbi.nlm.nih.gov/compound/Acetylcysteine
